Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sibenadet
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sibenadet is a unique dual-action small molecule agonist of both the **D2 dopamine receptor** and the **beta-2 adrenergic receptor**. It has been investigated primarily for the treatment of chronic obstructive pulmonary disease (COPD) and asthma due to its ability to produce bronchodilation through beta-2 adrenergic agonism, while also potentially reducing airway sensory nerve activity via the dopaminergic pathway. The dual mechanism may provide additional therapeutic benefits compared to targeting only one pathway, and sibenadet also has reported neuroprotective effects.
- Brand names
- Viozan
- Other names
- sibenadet hydrochloride
02
Targets
DRD2 (Dopamine D2 Receptor)ADRB2 (β2)
Beyond the preview
Go deeper on sibenadet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sibenadet.